Frédérique Penault–Llorca

7.0k total citations · 2 hit papers
20 papers, 3.3k citations indexed

About

Frédérique Penault–Llorca is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine. According to data from OpenAlex, Frédérique Penault–Llorca has authored 20 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Frédérique Penault–Llorca's work include HER2/EGFR in Cancer Research (6 papers), Ovarian cancer diagnosis and treatment (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Frédérique Penault–Llorca is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Ovarian cancer diagnosis and treatment (4 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Frédérique Penault–Llorca collaborates with scholars based in France, United States and United Kingdom. Frédérique Penault–Llorca's co-authors include Mathew J. Ellis, Seungmok Paik, J Cuzick, I E Smith, N. Lynn Henry, Tracy Lively, G. Viale, Roger A’Hern, Judith Hugh and Janine Salter and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Frédérique Penault–Llorca

17 papers receiving 3.2k citations

Hit Papers

Assessment of Ki67 in Breast Cancer: Recommendations from... 2008 2026 2014 2020 2011 2008 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
    2011 1.5k citations Torsten O. Nielsen, Roger A’Hern et al. JNCI Journal of the National Cancer Institute profile →
  2. KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
    2008 1.1k citations Astrid Lièvre, Jean‐Baptiste Bachet et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Frédérique Penault–Llorca France 10 2.3k 1.4k 823 734 707 20 3.3k
G. Viale Italy 14 1.7k 0.7× 1.4k 1.0× 511 0.6× 563 0.8× 807 1.1× 47 3.0k
David N. Church United Kingdom 28 1.7k 0.7× 1.3k 0.9× 1.2k 1.5× 687 0.9× 1.1k 1.5× 75 4.4k
Karin A. Oien United Kingdom 31 2.1k 0.9× 834 0.6× 555 0.7× 496 0.7× 1.1k 1.6× 64 3.6k
Atilla Ömeroğlu Canada 23 1.6k 0.7× 1.9k 1.4× 779 0.9× 476 0.6× 1.7k 2.4× 74 4.0k
William M. Sikov United States 26 2.3k 1.0× 1.7k 1.2× 553 0.7× 660 0.9× 590 0.8× 93 3.4k
Stacy L. Moulder United States 32 2.5k 1.1× 1.3k 0.9× 419 0.5× 922 1.3× 1.4k 2.0× 141 3.9k
Jan Lindebjerg Denmark 31 1.9k 0.8× 752 0.5× 590 0.7× 602 0.8× 678 1.0× 121 2.9k
Carolyn I. Sartor United States 30 2.5k 1.1× 2.0k 1.4× 756 0.9× 830 1.1× 1.5k 2.1× 51 4.3k
Soomin Ahn South Korea 27 1.2k 0.5× 533 0.4× 377 0.5× 647 0.9× 770 1.1× 132 2.6k
Peter Savas Australia 23 3.2k 1.4× 1.1k 0.8× 286 0.3× 1.0k 1.4× 1.0k 1.5× 49 4.3k

Countries citing papers authored by Frédérique Penault–Llorca

Since Specialization
Citations

This map shows the geographic impact of Frédérique Penault–Llorca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédérique Penault–Llorca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédérique Penault–Llorca more than expected).

Fields of papers citing papers by Frédérique Penault–Llorca

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédérique Penault–Llorca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédérique Penault–Llorca. The network helps show where Frédérique Penault–Llorca may publish in the future.

Co-authorship network of co-authors of Frédérique Penault–Llorca

This figure shows the co-authorship network connecting the top 25 collaborators of Frédérique Penault–Llorca. A scholar is included among the top collaborators of Frédérique Penault–Llorca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frédérique Penault–Llorca. Frédérique Penault–Llorca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Adam, Julien, Nolwenn Le Stang, Arnaud Uguen, et al.. (2023). Multicenter Harmonization Study of Pan-Trk Immunohistochemistry for the Detection of NTRK3 Fusions. Modern Pathology. 36(8). 100192–100192. 4 indexed citations
3.
Penault–Llorca, Frédérique, et al.. (2019). CHIP et cancers de l’ovaire : pour quelles patientes ?. Bulletin du Cancer. 106(11). 1023–1028. 1 indexed citations
4.
Dauplat, Marie-Mélanie, et al.. (2018). Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. BMC Cancer. 18(1). 129–129. 38 indexed citations
5.
6.
Bozec, Alexandre, Nathalie Ebran, Emmanuel Chamorey, et al.. (2016). Combination of phosphotidylinositol‐3‐kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer. Head & Neck. 39(1). 151–159. 18 indexed citations
7.
Lantuéjoul, Sylvie, Isabelle Rouquette, Hélène Blons, et al.. (2015). French multicentric validation ofALKrearrangement diagnostic in 547 lung adenocarcinomas. European Respiratory Journal. 46(1). 207–218. 42 indexed citations
8.
Tilleul, P., et al.. (2015). Impact Of Her2 Testing Quality Improvement From A Health Economic Perspective. Value in Health. 18(7). A373–A373. 1 indexed citations
9.
Chêne, Geneviève, J Dauplat, Nina Radosevic‐Robin, Anne Cayre, & Frédérique Penault–Llorca. (2013). The Fallopian tube odyssey: from the ovary to the tube. About high-grade serous ovarian carcinoma. Bulletin du Cancer. 100(7-8). 757–764. 5 indexed citations
10.
Penault–Llorca, Frédérique, et al.. (2013). [Diagnostic approach for breast cancer classification].. PubMed. 63(10). 1384–90.
11.
Nielsen, Torsten O., Roger A’Hern, R. Charles Coombes, et al.. (2011). Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. JNCI Journal of the National Cancer Institute. 103(22). 1656–1664. 1488 indexed citations breakdown →
12.
Spielmann, M., Henri Roché, T. Delozier, et al.. (2009). Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial. Journal of Clinical Oncology. 27(36). 6129–6134. 220 indexed citations
13.
Lièvre, Astrid, Jean‐Baptiste Bachet, Valérie Boige, et al.. (2008). KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. Journal of Clinical Oncology. 26(3). 374–379. 1141 indexed citations breakdown →
14.
Deligdisch, Liane, Peter Schlosshauer, Maoxin Wu, Albert Altchek, & Frédérique Penault–Llorca. (2008). Early Pathologic Diagnosis of Gynecologic Cancer Including a Clinician's View. WORLD SCIENTIFIC eBooks.
15.
Tuefferd, Marianne, Jérôme Couturier, Frédérique Penault–Llorca, et al.. (2007). HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients. PLoS ONE. 2(11). e1138–e1138. 144 indexed citations
16.
Lacroix‐Triki, Magali, Simone Mathoulin‐Pélissier, Jean‐Pierre Ghnassia, et al.. (2006). High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: A multicentre GEFPICS study. European Journal of Cancer. 42(17). 2946–2953. 40 indexed citations
17.
Cayre, Anne, et al.. (2004). Does99mTc-Sestamibi Uptake Discriminate Breast Tumors?. Cancer Investigation. 22(4). 498–504. 4 indexed citations
18.
Arnould, Laurent, Yves Denoux, Gaëtan MacGrogan, et al.. (2003). Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. British Journal of Cancer. 88(10). 1587–1591. 93 indexed citations
19.
Penault–Llorca, Frédérique & Anne Vincent‐Salomon. (2003). [Roles of the pathologist in neoadjuvant chemotherapy: evaluation of response, prognostic and predictive factors].. PubMed. 23(6). 555–63. 8 indexed citations
20.
Cayre, Anne, F. Cachin, J. Maublant, et al.. (2002). Single static view 99mTc-sestamibi scintimammography predicts response to neoadjuvant chemotherapy and is related to MDR expression. International Journal of Oncology. 20(5). 1049–55. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G. Viale Breakdown of academic impact, for papers by David N. Church Breakdown of academic impact, for papers by Karin A. Oien Breakdown of academic impact, for papers by Atilla Ömeroğlu Breakdown of academic impact, for papers by William M. Sikov Breakdown of academic impact, for papers by Stacy L. Moulder Breakdown of academic impact, for papers by Jan Lindebjerg Breakdown of academic impact, for papers by Carolyn I. Sartor Breakdown of academic impact, for papers by Soomin Ahn Breakdown of academic impact, for papers by Peter Savas
Rankless by CCL
2026